Skip to main content
. 2023 Nov-Dec;39(6):1847–1852. doi: 10.12669/pjms.39.6.7944

Table-I.

Patient baseline data.

Variables TACE+lenvatinib group (n=46) TACE group (n=57) t/ P
Gender, n (%) -0.348 0.728
  Male 29 (63.04) 34 (59.65)
  Female 17 (36.96) 23 (40.35)
Age, years, mean ± SD 51.52±6.31 52.12±5.71 -0.507 0.614
Body weight, kg, n (%) 0.004 0.997
  <60 kg 25 (54.35) 31 (54.39)
  ≥60 kg 21 (45.65) 26 (45.61)
ECOG score -0.184 0.854
  0 37 (80.43) 45 (78.95)
  1 9 (19.57) 12 (21.05)
Child-Pugh class, n(%) -0.220 0.826
  A 41 (89.13) 50 (87.72)
  B 5 (10.87) 7 (12.28)